Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial.
Saved in:
| Title: | Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial. |
|---|---|
| Authors: | Cao Y; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Li Q; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Guo W; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Xu M; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Fang K; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Wang F; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Zhang R; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Li L; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Wei J; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Liu Z; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Liang C; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Zhai W; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Ma Q; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Chen X; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Cao W; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Yang D; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., He Y; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Pang A; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Feng S; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Han M; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Sun J; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China., Jiang E; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin, China. |
| Source: | Frontiers in immunology [Front Immunol] 2025 Nov 28; Vol. 16, pp. 1626775. Date of Electronic Publication: 2025 Nov 28 (Print Publication: 2025). |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2025.1626775 |
